Linvoseltamab is a medicine used to treat multiple myeloma that has come back or stopped responding after several other treatments. It is given as an infusion into a vein. It works by linking the body's immune T cells to the cancer cells so the T cells can attack them.
Every report comes from a Lived member, sent anonymously.
Have you tried Lynozyfic (Linvoseltamab) for Multiple Myeloma?
Linvoseltamab, sold as Lynozyfic, is an immunotherapy for adults with multiple myeloma, a cancer of the plasma cells in the bone marrow. It is used when the myeloma has come back or stopped responding after at least four earlier lines of treatment, including three main drug families: a proteasome inhibitor such as bortezomib, an immunomodulatory drug such as lenalidomide, and an anti-CD38 antibody such as daratumumab. The US approval, granted in 2025, is an accelerated approval. That means it was based on how often and how long the cancer shrank in a study, not yet on proof that people live longer. Continued approval depends on results from ongoing confirmatory trials. It is not approved for children.
Linvoseltamab is a bispecific antibody, a lab-made protein with two different arms. One arm attaches to BCMA (B-cell maturation antigen), a protein found on the surface of myeloma cells. The other attaches to CD3, part of the switch that activates T cells, the immune cells that kill infected or abnormal cells. By holding a T cell and a myeloma cell close together, the drug switches the T cell on and directs it to destroy the cancer cell. This is why it is often called a T-cell engager. The same immune activation explains its main risks: activated T cells release signaling chemicals called cytokines, which can cause fever and other body-wide reactions, and some healthy antibody-making B cells also carry BCMA, which weakens defenses against infection.
Lynozyfic is given as an infusion into a vein by a cancer care team at a certified center. Treatment starts with a step-up schedule: a small first dose, a larger second dose a week later, and the full dose a week after that. Building up gradually lowers the chance and severity of cytokine release syndrome. People stay in the hospital for 24 hours after each of the first two step-up doses so they can be watched closely. Before the early doses, people receive premedications, usually a steroid (dexamethasone), acetaminophen and an antihistamine, to reduce reactions. After the step-up phase, the full dose is given weekly for about 10 weeks, then every two weeks. People who have a very good response that lasts to about six months of treatment can move to every four weeks. Treatment continues as long as it is working and side effects are manageable. Missed or delayed doses may mean restarting the step-up schedule, so timing is coordinated with the care team.
Cytokine release syndrome (CRS) is the best-known reaction and carries a boxed warning, the strongest warning the US Food and Drug Administration (FDA) requires. In the main study about half of people had it, usually mild, and most often within a day after the first step-up dose. It typically shows up as fever, chills, a fast heartbeat, dizziness or lightheadedness from low blood pressure, or shortness of breath. The second boxed warning covers nervous system effects, including a reaction called ICANS (immune effector cell-associated neurotoxicity syndrome). Signs include confusion, unusual sleepiness, trouble staying alert, or difficulty speaking or writing. They usually appear within a few days of a dose and can occur with or without CRS. Signs of either CRS or a nervous system reaction, at any point in treatment, need medical attention right away; people are given a wallet card that lists them. Infections are a major and ongoing risk, because the drug lowers infection-fighting white blood cells and antibodies. Serious infections such as pneumonia and sepsis affected about four in ten people in the study, and some were fatal. Fever, chills or new weakness should be reported to the care team immediately. Other common effects include muscle and joint pain, tiredness, cough, colds, diarrhea, nausea and headache. The drug can also raise liver enzymes; yellowing of the skin or eyes, dark urine or pain in the upper right belly should be reported.
Because of the risks of CRS and nervous system reactions, Lynozyfic is available only through a restricted safety program (a REMS, or Risk Evaluation and Mitigation Strategy). Only certified doctors and treatment centers can prescribe and give it. Carry the patient wallet card at all times and show it to any doctor, nurse or emergency team, since its reactions can look like other illnesses. Do not drive or operate heavy or dangerous machinery for 48 hours after each step-up dose, or at any time new confusion or drowsiness appears, until the symptoms have cleared. The cytokines released early in treatment can slow how the liver breaks down some other medicines, raising their levels. This matters most for drugs where a small change in level can cause harm, mainly during the first few weeks and around any episode of CRS. The care team should review every medicine and supplement. Linvoseltamab may harm a developing baby. A pregnancy test is done before starting, and effective birth control is advised during treatment and for 3 months after the last dose. Breastfeeding is not recommended for the same period.
In the study that led to approval, about 70% of people who had already been through four or more lines of treatment saw their myeloma shrink, and about 45% reached a complete response or better, meaning standard tests could no longer find the cancer. Responses usually began within about a month. Among those who responded, an estimated 72% were still responding a year later. Because the study had no comparison group, it cannot show yet how much the drug extends life. The first weeks are the most demanding, with hospital stays, frequent visits and close watching for reactions. Later, visits become less frequent. Regular blood tests track blood counts, liver function, antibody levels and the myeloma itself. Many people receive preventive medicines against certain viral and fungal infections, and some need antibody replacement infusions (immunoglobulin) to lower infection risk. Delays in treatment because of infections or low blood counts are common, and the care team adjusts the schedule as needed.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Lynozyfic (Linvoseltamab), what you've noticed, or ask the community a question.